Identification and Characterization of LPCAT4 as A Potential Drug Target

Target Name: LPCAT4

NCBI ID: G254531

LPCAT4

Identification and Characterization of LPCAT4 as A Potential Drug Target

LPCAT4 (1-acylglycerol-3-phosphate O-acyltransferase 7) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a key enzyme in the fatty acid oxidation pathway, which is involved in the breakdown of fatty acids to produce energy.

One of the unique features of LPCAT4 is its role in the production of 1,2-diacylglycerols (DAGs), which are crucial intermediates in the production of fatty acids. DAGs are formed from the oxidation of fatty acids, and they can then be used as a source of energy by the cell.

In addition to its role in fatty acid oxidation, LPCAT4 has also been shown to play a key role in the regulation of cellular signaling pathways. It has been shown to interact with various signaling molecules, including the transcription factor, nuclear factor kappa B (NF-kappa-B), and the protein, p53.

These interactions between LPCAT4 and signaling molecules have important implications for the regulation of cellular processes, including inflammation, metabolism, and cell survival.

Given its involvement in cellular signaling pathways, LPCAT4 has been identified as a potential drug target. Studies have shown that LPCAT4 inhibition has been shown to have a variety of therapeutic effects, including the inhibition of inflammation and the inhibition of cell growth.

In addition to its potential therapeutic uses, LPCAT4 has also been shown to be a valuable biomarker for a variety of diseases. For example, LPCAT4 has been shown to be decreased in individuals with certain metabolic disorders, such as non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

These findings suggest that LPCAT4 may be a useful biomarker for the diagnosis and treatment of these diseases. Additionally, the potential therapeutic effects of LPCAT4 make it a promising target for future drug development.

In conclusion, LPCAT4 is a protein that plays a crucial role in the fatty acid oxidation pathway and has been shown to interact with various signaling molecules. Its involvement in cellular signaling pathways and its potential as a drug target make it an attractive target for future research and development. Further studies are needed to fully understand the role of LPCAT4 in cellular processes and its potential as a drug target.

Protein Name: Lysophosphatidylcholine Acyltransferase 4

Functions: Displays acyl-CoA-dependent lysophospholipid acyltransferase activity with a subset of lysophospholipids as substrates; converts lysophosphatidylethanolamine to phosphatidylethanolamine, lysophosphatidylcholine to phosphatidycholine, 1-alkenyl-lysophatidylethanolamine to 1-alkenyl-phosphatidylethanolamine, lysophosphatidylglycerol and alkyl-lysophosphatidylcholine to phosphatidylglycerol and alkyl-phosphatidylcholine, respectively. In contrast, has no lysophosphatidylinositol, glycerol-3-phosphate, diacylglycerol or lysophosphatidic acid acyltransferase activity. Prefers long chain acyl-CoAs (C16, C18) as acyl donors

The "LPCAT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LPCAT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets